TNYA — Tenaya Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Tenaya Therapeutics Q2 Net Income USD -23.283 Million Vs. IBES Estimate USD -25.9 Million
Tenaya Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Tenaya Therapeutics Receives Positive Safety Reviews From Independent Dsmbs To Advance Both TN-201 And TN-401 Gene Therapy Clinical Trials As Designed
Brief: Tenaya Therapeutics Q1 Net Income USD -26.864 Million
Brief: Tenaya Therapeutics Inc - On Mar 27, Co Approves Restructuring Plan - SEC Filing
Brief: Tenaya Therapeutics files for mixed shelf offering of up to $300 mln
Brief: Tenaya Therapeutics Q4 Net Income USD -23.836 Million Vs. IBES Estimate USD -27.1 Million
U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth
U.S. STOCKS ON THE MOVE-Capricor, Wave Life Sciences, EVgo
U.S. STOCKS ON THE MOVE-Wellgistics, Capricor, Wave Life Sciences
U.S. STOCKS ON THE MOVE-Target, Nvidia, Tesla
Tenaya Therapeutics plumbs new lows on stock-and-warrants offering
Brief: Tenaya Therapeutics Announces Pricing Of Public Offering
Brief: Tenaya Therapeutics Announces Proposed Public Offering
Brief: Tenaya Therapeutics To Announce Initial Data From Mypeak-1 Phase 1B/2 Clinical Trial Of TN-201 Gene Therapy For Mybpc3-Associated Hypertrophic Cardiomyopathy On Tuesday, December 17, 2024
Brief: Tenaya Therapeutics Doses First Patient In Ridge-1 Phase 1B Clinical Trial Of TN-401
Brief: Tenaya Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tenaya Therapeutics Q3 Net Income USD -25.634 Million Vs. IBES Estimate USD -31.1 Million
Brief: Tenaya Therapeutics Announces Updates On TN-201 Gene Therapy Program For MYBPC3-Associated HCM